Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych VivasGeneral adult psychiatry — anxiety disorders

Psych Vivas · General adult psychiatry — anxiety disorders

Social anxiety disorder — structured clinical viva

Fellowship viva covering chronic SAD, alcohol safety behaviour, inadequate prior SSRI trials, Clark/Wells CBT targets, and evidence-based medication including maintenance and specialist MAOI context.

clinical
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
You are the psychiatry registrar. A 26-year-old software engineer has avoided team meetings and client calls for 3 years, fearing colleagues will see him blush and judge him as incompetent. He drinks before any social gathering. Two SSRI trials were stopped within 10 days for 'feeling worse'. He asks for 'something stronger than talking' and declines exposure work because 'I already know I am awkward'. Discuss formulation, criteria (including performance-only), CBT rationale targeting safety behaviours and self-focused attention, medication sequencing, alcohol, and refractory options including phenelzine specialist role.

Interpretation

Reveal interpretation

This is generalised social anxiety disorder (interactional and performance situations) with alcohol as a safety behaviour and inadequate prior antidepressant trials (stopped within 10 days — not therapeutic dose/duration). The belief "I already know I am awkward" is a treatment target (distorted self-image / certainty without behavioural experiments), not a reason to abandon CBT. Do not escalate long-term benzodiazepines as the primary plan.[1][4][5]

Formulation. Vulnerability (possible behavioural inhibition/temperament), maintaining factors (self-focused attention, safety behaviours including alcohol, post-event processing, avoidance of meetings), precipitants (workplace demands), and iatrogenic history of aborted SSRI trials without activation management.[1]

SSRI re-challenge strategy. Explain early activation; start low (e.g. sertraline 25 mg), frequent early review, short-term non-escalating support, parallel CBT engagement work. Prior "failure" at 10 days is not pharmacological non-response.[3][5]

CBT sales pitch without collusion. Validate distress; introduce experiments testing whether others notice blushing as much as feared; attention training; video feedback; drop alcohol-as-safety-behaviour experiments with medical support if dependence risk high.[1][4]

Specialist ladder. If true non-response after adequate SSRI/SNRI and quality CBT: switch class, combination, refractory pathway; phenelzine has landmark comparative efficacy versus CBGT but requires specialist MAOI counselling (diet, interactions, washout).[2][5]

Maintenance. After response, continue medication for a substantial period — sertraline continuation reduces relapse versus placebo substitution in responders.[6]

Key points

Ten days is not a failed SSRI trial

Therapeutic trials need dose, weeks of exposure, adherence and activation management — not abandonment at first jitteriness.

Alcohol maintains SAD

It is a safety behaviour and dependence risk, not an anxiolytic treatment plan.

CBT targets process, not pep talks

Self-focused attention, safety behaviours, negative self-image and post-event processing are the active ingredients.[1][4]

Escalating viva questions

  1. Reproduce DSM-5-TR social anxiety criteria and the performance-only specifier.
  2. How do you discriminate SAD from avoidant personality disorder and ASD?
  3. Name three CBT ingredients for SAD with rationale.
  4. Give a first-line drug with start dose, therapeutic range and early monitoring.
  5. What did Heimberg 1998 and Walker 2000 contribute? [2][3][6]

References

  1. [1]Stein MB, Stein DJ Social anxiety disorder Lancet, 2008.PMID 18374843
  2. [2]Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome Arch Gen Psychiatry, 1998.PMID 9862558
  3. [3]Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia Am J Psychiatry, 2001.PMID 11156811
  4. [4]Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis Lancet Psychiatry, 2014.PMID 26361000
  5. [5]Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders BMC Psychiatry, 2014.PMID 25081580
  6. [6]Walker JR, Van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment J Clin Psychopharmacol, 2000.PMID 11106135